-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
DENV-IN-4
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/2762302-75-8.gif)
| Category | Human immunodeficiency Virus (HIV) |
| CAS | 2762302-75-8 |
| Description | DENV-IN-4 is a specific inhibitor targeting the Dengue virus (DENV), specifically the serotype 4. Dengue fever is caused by four different serotypes of the virus (DENV-1 to DENV-4), and researchers develop inhibitors and vaccines to combat each serotype. DENV-IN-4 would be a compound or drug designed to inhibit the activity of the Dengue virus serotype 4, potentially by interfering with the virus's ability to replicate or bind to host cells. These inhibitors are crucial for developing treatments and vaccines against dengue fever, especially in regions where the virus is endemic. |
Product Information
| Synonyms | 1H-Imidazo[1,5-a]indol-1-one, 3-[4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]-2,3,9,9a-tetrahydro-2-[(4-nitrophenyl)amino]-, (3R,9aS)-; (3R,9aS)-3-[4-[[(1,1-Dimethylethyl)dimethylsilyl]oxy]phenyl]-2,3,9,9a-tetrahydro-2-[(4-nitrophenyl)amino]-1H-imidazo[1,5-a]indol-1-one; (3R,9aS)-3-(4-((tert-Butyldimethylsilyl)oxy)phenyl)-2-((4-nitrophenyl)amino)-2,3,9,9a-tetrahydro-1H-imidazo[1,5-a]indol-1-one |
| IUPAC Name | (1R,3aS)-1-[4-[tert-butyl(dimethyl)silyl]oxyphenyl]-2-(4-nitroanilino)-3a,4-dihydro-1H-imidazo[1,5-a]indol-3-one |
| Molecular Weight | 516.66 |
| Molecular Formula | C28H32N4O4Si |
| Canonical SMILES | O=C1N(NC2=CC=C(C=C2)N(=O)=O)C(C3=CC=C(O[Si](C)(C)C(C)(C)C)C=C3)N4C=5C=CC=CC5CC14 |
| InChI | InChI=1S/C28H32N4O4Si/c1-28(2,3)37(4,5)36-23-16-10-19(11-17-23)26-30-24-9-7-6-8-20(24)18-25(30)27(33)31(26)29-21-12-14-22(15-13-21)32(34)35/h6-17,25-26,29H,18H2,1-5H3/t25-,26+/m0/s1 |
| InChIKey | ZDPOOVOOOPKULV-IZZNHLLZSA-N |
| Boiling Point | 615.5±65.0 °C at 760 mmHg |
| Purity | ≥98% by HPLC |
| Density | 1.27±0.1 g/cm3 |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Complexity | 842 |
| Exact Mass | 516.21928205 |
| In Vitro | DENV-IN-4 (compound 15) (0.064-200 μM; 3 days) has antiviral effects independent of its toxicity (DENV EC50 = 4.79 μM, Vero CC50>100, SI>20.9). DENV-IN-4 (3.125-50 μM in Vero and 3.75-30 μM in A549 and Huh-7; 48 h) inhibits the expression level of DENV2 and is concentration-dependent with a smoother inhibition curve in Vero. DENV-IN-4 (7.5 and 15 μM; 48 h) potently inhibits DENV infection in Vero cells and is completely inhibited at 15 μM. DENV-IN-4(0-15μM; 48 h) inhibits the production of DENV2E protein in Vero cells with good concentration dependence. Result: The antiviral effect of DENV-IN-4 was shown to be independent of its toxicity (Vero EC50 = 4.79 μM, CC50>100, SI>20.9). |
| Target | HIV (IIIB): 0.1512 μM (EC50) DENV-I: 1.47 μM (EC50) DENV-III: 7.08 μM (EC50) DENV-IV: 8.91 μM (EC50) DENV-II: 9.23 μM (EC50) |
| XLogP3-AA | 6.3 |
